

Zydus receives final approval from the USFDA for Ezetimibe Tablets USP

The drug is used to reduce high cholesterol levels

Ahmedabad, 13 June 2017

Zydus Cadila has received the final approval from the USFDA to market Ezetimibe Tablets USP, 10 mg. Ezetimibe is a drug used to reduce high cholesterol levels. It will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The estimated sales for Ezetimibe Tablets is \$2.7 billion as per IMS MAT April 2017.

The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
